FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
GlobalData on MSN6d
FDA approves Roche’s Tecentriq Hybreza for cancer
The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
FiercePharma6d
After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...
Cure Today6d
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...
Managed Healthcare Executive6d
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
Zacks.com on MSN6d
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug ...
Medscape3d
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...
Monthly Prescribing Reference6d
FDA Approves Tecentriq Hybreza, a Subcutaneously Administered PD-L1 Inhibitor
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and ...